amsacrine

(redirected from M-AMSA)
Also found in: Acronyms.

amsacrine

A topoisomerase inhibitor with antineoplastic activity; it can also intercalate into the DNA of tumour cells, altering major and minor grooves therein, thereby inhibiting DNA replication and transcription by reducing association between the altered DNA and DNA polymerase, RNA polymerase and transcription factors.

Indications
Acute lymphoblastic leukaemia, lymphoma.

Adverse effects
Bone marrow suppression.

amsacrine

A cytotoxic drug used to treat acute myeloid leukaemia. A brand name is Amsidine.
References in periodicals archive ?
Topo II poisons such as m-AMSA are known to stabilise the cleavage complex that leads to DNA strand breaks, while catalytic inhibitors such as aclarubicin can protect cells against Topo II poison-induced DNA damage.
Evodiamine was demonstrated to have cytotoxicity against both K562 and THP-1, but m-AMSA (K562, [IC.sub.50] 0.91 [micro]M) and etoposide (THP-1, IC50 9.61 [micro]M) still out-performed evodiamine in either assay.
Abbreviations: CPT, camptothecin; DMSO, dimethylsulphoxide; EtBr, ethidium bromide; m-AMSA, amsacrine; MTT, 3-(4,5-dimethyl thiazol-2yl)-2,5-diphemyltetrazolium bromide; Nck, nicked; Rely relaxed; Sc, supercoiled; Topo I, topoisomerase I; Topo II, topoisomerase II.